Truist Financial Boosts Integer (NYSE:ITGR) Price Target to $145.00

Integer (NYSE:ITGR) had its price objective increased by research analysts at Truist Financial from $137.00 to $145.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s target price points to a potential upside of 12.05% from the stock’s previous close.

Several other equities analysts have also commented on the stock. Oppenheimer assumed coverage on shares of Integer in a research report on Tuesday, July 16th. They set an “outperform” rating and a $135.00 price target for the company. Benchmark reissued a “buy” rating and set a $130.00 target price on shares of Integer in a research report on Friday, August 2nd. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $135.00.

Integer Price Performance

Shares of ITGR traded down $0.59 during trading hours on Tuesday, reaching $129.41. 1,939 shares of the company traded hands, compared to its average volume of 315,947. The stock has a market capitalization of $4.34 billion, a PE ratio of 44.51, a price-to-earnings-growth ratio of 1.87 and a beta of 1.09. The company has a quick ratio of 1.96, a current ratio of 3.29 and a debt-to-equity ratio of 0.73. The stock has a fifty day simple moving average of $123.35 and a 200 day simple moving average of $119.22. Integer has a fifty-two week low of $69.40 and a fifty-two week high of $131.87.

Integer (NYSE:ITGR) last announced its earnings results on Thursday, July 25th. The medical equipment provider reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.06. Integer had a net margin of 6.31% and a return on equity of 11.48%. The firm had revenue of $436.20 million for the quarter, compared to analyst estimates of $437.00 million. During the same quarter last year, the business earned $1.14 earnings per share. Integer’s revenue was up 9.0% compared to the same quarter last year. As a group, research analysts predict that Integer will post 5.31 EPS for the current fiscal year.

Insider Buying and Selling at Integer

In other Integer news, Director Jean M. Hobby sold 11,960 shares of the firm’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $119.66, for a total transaction of $1,431,133.60. Following the completion of the transaction, the director now directly owns 2,280 shares of the company’s stock, valued at approximately $272,824.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ITGR. Quest Partners LLC lifted its stake in Integer by 3,688.9% during the second quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 332 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Integer by 60.9% in the 2nd quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 142 shares during the period. Headlands Technologies LLC acquired a new position in Integer in the first quarter valued at approximately $106,000. Innealta Capital LLC bought a new position in shares of Integer during the second quarter valued at approximately $110,000. Finally, Hancock Whitney Corp bought a new stake in shares of Integer in the 1st quarter worth approximately $203,000. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.